Tusamitamab Ravtansine Does Not Extend Survival With Nonsquamous NSCLC
Findings seen in patients previously treated with platinum-based chemotherapy and immunotherapy whose tumors highly expressed CEACAM5
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.